Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: RT who wrote (12357)	7/31/1998 3:55:00 PM
From: Mkilloran	Respond to of 23519

rt...and if they just signup a mkt partner for the USA is that so bad??? As long as the new partner can get the script count to rise that would prove the point that Vivus will do fine in a worldwide market. We can get the same proof when Viagra is sold in a country that Astra / Janssen are selling Muse. How big/small of a piece of the ED market will MUSE control??? Then Alibra should get more later. PW thinks enough to get $1.00 eps next year...at a modest pe multiple of 20 times earnings you get $20 a share.....the adv pe multiple in this field is 35 today.

To: RT who wrote (12357)	7/31/1998 4:07:00 PM
From: VLAD	Respond to of 23519

RT, I would wager that most of the shorts are hedged positions so it really doesn't matter where the stocks price ends up.